Glycated Hemoglobin Levels Predictive of Liraglutide Treatment Response in T2D










Baseline HbA1c and, to some extent, diabetes duration were the primary drivers of degree of treatment response to liraglutide.




Treatment response in patients with type 2 diabetes (T2D) receiving liraglutide was correlated with diabetes duration and glycated hemoglobin (HbA1c) levels, according to a study published in Acta Diabetologica.

Medical records from participants in the ReaL observational study (ClinicalTrials.gov identifier:

NCT02255266) with T2D receiving liraglutide for the first time were evaluated and compared between groups who either did (n=577) or did not (n=748) achieve an HbA1c reduction of ≥1.0 percentage point. Information from the records included fasting plasma glucose, body weight, body mass index, diabetes duration, presence of diabetes complications, and diabetes treatments.

Leave a Reply

Your email address will not be published. Required fields are marked *